home / stock / tlsa / tlsa news

TLSA News and Press, Tiziana Life Sciences plc From 10/29/25

Stock Information
Company Name: Tiziana Life Sciences plc
Stock Symbol: TLSA
Market: NASDAQ
Website: tizianalifesciences.com
Menu
TLSA TLSA Quote TLSA Short TLSA News TLSA Articles TLSA Message Board
Get TLSA Alerts

News, Short Squeeze, Breakout and More Instantly...
TLSA - Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy

BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, ...
TLSA - Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia

BOSTON, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human,...

TLSA - Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody

BOSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), today announces it will advance its second asset, a fully human anti-IL-6 receptor (“IL-6R”) monoclonal antibody, TZLS-501. There has ...

TLSA - Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress

BOSTON, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human,...
TLSA - Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury

BOSTON, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human,...

TLSA - Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

BOSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human,...

TLSA - Tiziana Life Sciences rises premarket after Chairman boosts stake

2025-09-05 09:23:02 ET More on Tiziana Life Sciences Tiziana: Scope Of Foralumab Goes Beyond That Of Multiple Sclerosis Targeting Seeking Alpha’s Quant Rating on Tiziana Life Sciences Historical earnings data for Tiziana Life Sciences Financial informa...
TLSA - Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy

BOSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, ...

TLSA - Tiziana to begin testing foralumab in multiple system atrophy

2025-08-11 09:29:05 ET More on Tiziana Life Sciences Tiziana: Scope Of Foralumab Goes Beyond That Of Multiple Sclerosis Targeting Seeking Alpha’s Quant Rating on Tiziana Life Sciences Historical earnings data for Tiziana Life Sciences Financial informa...

TLSA - FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy

NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human...
Previous 10 Next 10